nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Pancytopenia—Doxorubicin—pancreatic cancer	0.000481	0.000481	CcSEcCtD
Methylphenidate—Asthenia—Irinotecan—pancreatic cancer	0.000479	0.000479	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000478	0.000478	CcSEcCtD
Methylphenidate—Conjunctivitis—Epirubicin—pancreatic cancer	0.000474	0.000474	CcSEcCtD
Methylphenidate—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000471	0.000471	CcSEcCtD
Methylphenidate—Dry mouth—Docetaxel—pancreatic cancer	0.000471	0.000471	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.00047	0.00047	CcSEcCtD
Methylphenidate—Sweating—Epirubicin—pancreatic cancer	0.000468	0.000468	CcSEcCtD
Methylphenidate—Asthenia—Gemcitabine—pancreatic cancer	0.000466	0.000466	CcSEcCtD
Methylphenidate—Haematuria—Epirubicin—pancreatic cancer	0.000465	0.000465	CcSEcCtD
Methylphenidate—Confusional state—Docetaxel—pancreatic cancer	0.000465	0.000465	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000462	0.000462	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000461	0.000461	CcSEcCtD
Methylphenidate—Oedema—Docetaxel—pancreatic cancer	0.000461	0.000461	CcSEcCtD
Methylphenidate—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000461	0.000461	CcSEcCtD
Methylphenidate—Weight increased—Doxorubicin—pancreatic cancer	0.000461	0.000461	CcSEcCtD
Methylphenidate—Epistaxis—Epirubicin—pancreatic cancer	0.00046	0.00046	CcSEcCtD
Methylphenidate—Pruritus—Gemcitabine—pancreatic cancer	0.00046	0.00046	CcSEcCtD
Methylphenidate—Infection—Docetaxel—pancreatic cancer	0.000458	0.000458	CcSEcCtD
Methylphenidate—Weight decreased—Doxorubicin—pancreatic cancer	0.000458	0.000458	CcSEcCtD
Methylphenidate—Sinusitis—Epirubicin—pancreatic cancer	0.000458	0.000458	CcSEcCtD
Methylphenidate—Diarrhoea—Irinotecan—pancreatic cancer	0.000456	0.000456	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—pancreatic cancer	0.000454	0.000454	CcSEcCtD
Methylphenidate—Shock—Docetaxel—pancreatic cancer	0.000454	0.000454	CcSEcCtD
Methylphenidate—Nervous system disorder—Docetaxel—pancreatic cancer	0.000452	0.000452	CcSEcCtD
Methylphenidate—Pruritus—Fluorouracil—pancreatic cancer	0.000452	0.000452	CcSEcCtD
Methylphenidate—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000452	0.000452	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—pancreatic cancer	0.000451	0.000451	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—pancreatic cancer	0.000451	0.000451	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—pancreatic cancer	0.000451	0.000451	CcSEcCtD
Methylphenidate—Tachycardia—Docetaxel—pancreatic cancer	0.00045	0.00045	CcSEcCtD
Methylphenidate—Skin disorder—Docetaxel—pancreatic cancer	0.000448	0.000448	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000447	0.000447	CcSEcCtD
Methylphenidate—Bradycardia—Epirubicin—pancreatic cancer	0.000446	0.000446	CcSEcCtD
Methylphenidate—Diarrhoea—Gemcitabine—pancreatic cancer	0.000445	0.000445	CcSEcCtD
Methylphenidate—Dizziness—Irinotecan—pancreatic cancer	0.000441	0.000441	CcSEcCtD
Methylphenidate—Haemoglobin—Epirubicin—pancreatic cancer	0.00044	0.00044	CcSEcCtD
Methylphenidate—Anorexia—Docetaxel—pancreatic cancer	0.00044	0.00044	CcSEcCtD
Methylphenidate—Rhinitis—Epirubicin—pancreatic cancer	0.000439	0.000439	CcSEcCtD
Methylphenidate—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000439	0.000439	CcSEcCtD
Methylphenidate—Haemorrhage—Epirubicin—pancreatic cancer	0.000438	0.000438	CcSEcCtD
Methylphenidate—Diarrhoea—Fluorouracil—pancreatic cancer	0.000437	0.000437	CcSEcCtD
Methylphenidate—Pharyngitis—Epirubicin—pancreatic cancer	0.000435	0.000435	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—pancreatic cancer	0.000433	0.000433	CcSEcCtD
Methylphenidate—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000432	0.000432	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—pancreatic cancer	0.00043	0.00043	CcSEcCtD
Methylphenidate—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00043	0.00043	CcSEcCtD
Methylphenidate—Urethral disorder—Epirubicin—pancreatic cancer	0.000429	0.000429	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000427	0.000427	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—pancreatic cancer	0.000426	0.000426	CcSEcCtD
Methylphenidate—Vomiting—Irinotecan—pancreatic cancer	0.000424	0.000424	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—pancreatic cancer	0.000423	0.000423	CcSEcCtD
Methylphenidate—Dizziness—Fluorouracil—pancreatic cancer	0.000423	0.000423	CcSEcCtD
Methylphenidate—Visual impairment—Epirubicin—pancreatic cancer	0.000422	0.000422	CcSEcCtD
Methylphenidate—Rash—Irinotecan—pancreatic cancer	0.000421	0.000421	CcSEcCtD
Methylphenidate—Dermatitis—Irinotecan—pancreatic cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Headache—Irinotecan—pancreatic cancer	0.000418	0.000418	CcSEcCtD
Methylphenidate—Insomnia—Docetaxel—pancreatic cancer	0.000417	0.000417	CcSEcCtD
Methylphenidate—Paraesthesia—Docetaxel—pancreatic cancer	0.000414	0.000414	CcSEcCtD
Methylphenidate—Erythema multiforme—Epirubicin—pancreatic cancer	0.000414	0.000414	CcSEcCtD
Methylphenidate—Vomiting—Gemcitabine—pancreatic cancer	0.000413	0.000413	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—pancreatic cancer	0.000412	0.000412	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—pancreatic cancer	0.000411	0.000411	CcSEcCtD
Methylphenidate—Somnolence—Docetaxel—pancreatic cancer	0.00041	0.00041	CcSEcCtD
Methylphenidate—Rash—Gemcitabine—pancreatic cancer	0.00041	0.00041	CcSEcCtD
Methylphenidate—Dermatitis—Gemcitabine—pancreatic cancer	0.000409	0.000409	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—pancreatic cancer	0.000409	0.000409	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—pancreatic cancer	0.000407	0.000407	CcSEcCtD
Methylphenidate—Headache—Gemcitabine—pancreatic cancer	0.000407	0.000407	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—pancreatic cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—pancreatic cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Vomiting—Fluorouracil—pancreatic cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—pancreatic cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Dyspepsia—Docetaxel—pancreatic cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—pancreatic cancer	0.000405	0.000405	CcSEcCtD
Methylphenidate—Rash—Fluorouracil—pancreatic cancer	0.000403	0.000403	CcSEcCtD
Methylphenidate—Dermatitis—Fluorouracil—pancreatic cancer	0.000403	0.000403	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—pancreatic cancer	0.000402	0.000402	CcSEcCtD
Methylphenidate—Decreased appetite—Docetaxel—pancreatic cancer	0.000401	0.000401	CcSEcCtD
Methylphenidate—Headache—Fluorouracil—pancreatic cancer	0.0004	0.0004	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.0004	0.0004	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000398	0.000398	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000398	0.000398	CcSEcCtD
Methylphenidate—Fatigue—Docetaxel—pancreatic cancer	0.000398	0.000398	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—pancreatic cancer	0.000397	0.000397	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—pancreatic cancer	0.000397	0.000397	CcSEcCtD
Methylphenidate—Nausea—Irinotecan—pancreatic cancer	0.000396	0.000396	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—pancreatic cancer	0.000395	0.000395	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000395	0.000395	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—pancreatic cancer	0.000394	0.000394	CcSEcCtD
Methylphenidate—Pain—Docetaxel—pancreatic cancer	0.000394	0.000394	CcSEcCtD
Methylphenidate—Chills—Epirubicin—pancreatic cancer	0.000393	0.000393	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—pancreatic cancer	0.000391	0.000391	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—pancreatic cancer	0.00039	0.00039	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—pancreatic cancer	0.000387	0.000387	CcSEcCtD
Methylphenidate—Nausea—Gemcitabine—pancreatic cancer	0.000386	0.000386	CcSEcCtD
Methylphenidate—Mental disorder—Epirubicin—pancreatic cancer	0.000384	0.000384	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000383	0.000383	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—pancreatic cancer	0.000381	0.000381	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—pancreatic cancer	0.000381	0.000381	CcSEcCtD
Methylphenidate—Feeling abnormal—Docetaxel—pancreatic cancer	0.00038	0.00038	CcSEcCtD
Methylphenidate—Nausea—Fluorouracil—pancreatic cancer	0.00038	0.00038	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—pancreatic cancer	0.000379	0.000379	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000377	0.000377	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—pancreatic cancer	0.000376	0.000376	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000376	0.000376	CcSEcCtD
Methylphenidate—Tension—Epirubicin—pancreatic cancer	0.000374	0.000374	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—pancreatic cancer	0.00037	0.00037	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—pancreatic cancer	0.000369	0.000369	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—pancreatic cancer	0.000368	0.000368	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—pancreatic cancer	0.000366	0.000366	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—pancreatic cancer	0.000366	0.000366	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000365	0.000365	CcSEcCtD
Methylphenidate—Abdominal pain—Docetaxel—pancreatic cancer	0.000365	0.000365	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—pancreatic cancer	0.000365	0.000365	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—pancreatic cancer	0.000364	0.000364	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—pancreatic cancer	0.000362	0.000362	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—pancreatic cancer	0.000359	0.000359	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—pancreatic cancer	0.000358	0.000358	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—pancreatic cancer	0.000355	0.000355	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000354	0.000354	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—pancreatic cancer	0.000353	0.000353	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—pancreatic cancer	0.000353	0.000353	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—pancreatic cancer	0.000352	0.000352	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—pancreatic cancer	0.00035	0.00035	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—pancreatic cancer	0.000346	0.000346	CcSEcCtD
Methylphenidate—Malaise—Epirubicin—pancreatic cancer	0.000344	0.000344	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—pancreatic cancer	0.000343	0.000343	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—pancreatic cancer	0.000342	0.000342	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—pancreatic cancer	0.000342	0.000342	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—pancreatic cancer	0.000341	0.000341	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—pancreatic cancer	0.000341	0.000341	CcSEcCtD
Methylphenidate—Hypersensitivity—Docetaxel—pancreatic cancer	0.00034	0.00034	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—pancreatic cancer	0.000339	0.000339	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—pancreatic cancer	0.000337	0.000337	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—pancreatic cancer	0.000335	0.000335	CcSEcCtD
Methylphenidate—Cough—Epirubicin—pancreatic cancer	0.000333	0.000333	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—pancreatic cancer	0.000332	0.000332	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—pancreatic cancer	0.000331	0.000331	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—pancreatic cancer	0.00033	0.00033	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—pancreatic cancer	0.000329	0.000329	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000327	0.000327	CcSEcCtD
Methylphenidate—Pruritus—Docetaxel—pancreatic cancer	0.000326	0.000326	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—pancreatic cancer	0.000326	0.000326	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—pancreatic cancer	0.000324	0.000324	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—pancreatic cancer	0.000324	0.000324	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—pancreatic cancer	0.000324	0.000324	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—pancreatic cancer	0.000324	0.000324	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—pancreatic cancer	0.000323	0.000323	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000322	0.000322	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—pancreatic cancer	0.000321	0.000321	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—pancreatic cancer	0.000318	0.000318	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—pancreatic cancer	0.000317	0.000317	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—pancreatic cancer	0.000317	0.000317	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—pancreatic cancer	0.000316	0.000316	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—pancreatic cancer	0.000316	0.000316	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—pancreatic cancer	0.000316	0.000316	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—pancreatic cancer	0.000314	0.000314	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—pancreatic cancer	0.000312	0.000312	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000311	0.000311	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—pancreatic cancer	0.000311	0.000311	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—pancreatic cancer	0.00031	0.00031	CcSEcCtD
Methylphenidate—Infection—Epirubicin—pancreatic cancer	0.000309	0.000309	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—pancreatic cancer	0.000308	0.000308	CcSEcCtD
Methylphenidate—Shock—Epirubicin—pancreatic cancer	0.000306	0.000306	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—pancreatic cancer	0.000306	0.000306	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—pancreatic cancer	0.000305	0.000305	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—pancreatic cancer	0.000305	0.000305	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000305	0.000305	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—pancreatic cancer	0.000304	0.000304	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—pancreatic cancer	0.000304	0.000304	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—pancreatic cancer	0.000302	0.000302	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000301	0.000301	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—pancreatic cancer	0.0003	0.0003	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—pancreatic cancer	0.0003	0.0003	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—pancreatic cancer	0.0003	0.0003	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—pancreatic cancer	0.000299	0.000299	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000298	0.000298	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—pancreatic cancer	0.000297	0.000297	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—pancreatic cancer	0.000297	0.000297	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—pancreatic cancer	0.000294	0.000294	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—pancreatic cancer	0.000293	0.000293	CcSEcCtD
Methylphenidate—Rash—Docetaxel—pancreatic cancer	0.000291	0.000291	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—pancreatic cancer	0.000291	0.000291	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—pancreatic cancer	0.00029	0.00029	CcSEcCtD
Methylphenidate—Headache—Docetaxel—pancreatic cancer	0.000289	0.000289	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000288	0.000288	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—pancreatic cancer	0.000288	0.000288	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—pancreatic cancer	0.000286	0.000286	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000283	0.000283	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—pancreatic cancer	0.000283	0.000283	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000282	0.000282	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000282	0.000282	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—pancreatic cancer	0.000281	0.000281	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—pancreatic cancer	0.000281	0.000281	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—pancreatic cancer	0.00028	0.00028	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—pancreatic cancer	0.000279	0.000279	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000278	0.000278	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—pancreatic cancer	0.000277	0.000277	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—pancreatic cancer	0.000277	0.000277	CcSEcCtD
Methylphenidate—Anorexia—Doxorubicin—pancreatic cancer	0.000274	0.000274	CcSEcCtD
Methylphenidate—Nausea—Docetaxel—pancreatic cancer	0.000274	0.000274	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—pancreatic cancer	0.000274	0.000274	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—pancreatic cancer	0.00027	0.00027	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000269	0.000269	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—pancreatic cancer	0.000268	0.000268	CcSEcCtD
Methylphenidate—Pain—Epirubicin—pancreatic cancer	0.000266	0.000266	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—pancreatic cancer	0.000266	0.000266	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000262	0.000262	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—pancreatic cancer	0.00026	0.00026	CcSEcCtD
Methylphenidate—Paraesthesia—Doxorubicin—pancreatic cancer	0.000258	0.000258	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—pancreatic cancer	0.000257	0.000257	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—pancreatic cancer	0.000256	0.000256	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—pancreatic cancer	0.000256	0.000256	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000254	0.000254	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—pancreatic cancer	0.000253	0.000253	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—pancreatic cancer	0.00025	0.00025	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000248	0.000248	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—pancreatic cancer	0.000248	0.000248	CcSEcCtD
Methylphenidate—Urticaria—Epirubicin—pancreatic cancer	0.000247	0.000247	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—pancreatic cancer	0.000246	0.000246	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—pancreatic cancer	0.000246	0.000246	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—pancreatic cancer	0.000246	0.000246	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—pancreatic cancer	0.000246	0.000246	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000237	0.000237	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000235	0.000235	CcSEcCtD
Methylphenidate—Hypersensitivity—Epirubicin—pancreatic cancer	0.000229	0.000229	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—pancreatic cancer	0.000229	0.000229	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—pancreatic cancer	0.000228	0.000228	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—pancreatic cancer	0.000228	0.000228	CcSEcCtD
Methylphenidate—Asthenia—Epirubicin—pancreatic cancer	0.000223	0.000223	CcSEcCtD
Methylphenidate—Pruritus—Epirubicin—pancreatic cancer	0.00022	0.00022	CcSEcCtD
Methylphenidate—Diarrhoea—Epirubicin—pancreatic cancer	0.000213	0.000213	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000212	0.000212	CcSEcCtD
Methylphenidate—Asthenia—Doxorubicin—pancreatic cancer	0.000207	0.000207	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—pancreatic cancer	0.000206	0.000206	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—pancreatic cancer	0.000204	0.000204	CcSEcCtD
Methylphenidate—Vomiting—Epirubicin—pancreatic cancer	0.000198	0.000198	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—pancreatic cancer	0.000197	0.000197	CcSEcCtD
Methylphenidate—Rash—Epirubicin—pancreatic cancer	0.000196	0.000196	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—pancreatic cancer	0.000196	0.000196	CcSEcCtD
Methylphenidate—Headache—Epirubicin—pancreatic cancer	0.000195	0.000195	CcSEcCtD
Methylphenidate—Dizziness—Doxorubicin—pancreatic cancer	0.00019	0.00019	CcSEcCtD
Methylphenidate—Nausea—Epirubicin—pancreatic cancer	0.000185	0.000185	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—pancreatic cancer	0.000183	0.000183	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—pancreatic cancer	0.000181	0.000181	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—pancreatic cancer	0.000181	0.000181	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—pancreatic cancer	0.00018	0.00018	CcSEcCtD
Methylphenidate—Nausea—Doxorubicin—pancreatic cancer	0.000171	0.000171	CcSEcCtD
